CPF: an Orphan Nuclear Receptor That Regulates Liver-Specific Expression of the Human Cholesterol 7␣-Hydroxylase Gene

Total Page:16

File Type:pdf, Size:1020Kb

CPF: an Orphan Nuclear Receptor That Regulates Liver-Specific Expression of the Human Cholesterol 7␣-Hydroxylase Gene Proc. Natl. Acad. Sci. USA Vol. 96, pp. 6660–6665, June 1999 Biochemistry CPF: An orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7a-hydroxylase gene MASAHIRO NITTA*, SHERRY KU,CHALINE BROWN,ARTHUR Y. OKAMOTO, AND BEI SHAN† Biology Department, Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080 Communicated by Steven L. McKnight, University of Texas Southwestern Medical Center, Dallas, TX, April 12, 1999 (received for review February 17, 1999) ABSTRACT Cholesterol 7a-hydroxylase is the first and Although the sterol regulatory element binding protein rate-limiting enzyme in a pathway through which cholesterol pathway, which is responsible for regulating genes involved in is metabolized to bile acids. The gene encoding cholesterol cholesterol uptake and biosynthesis, is well characterized, the 7a-hydroxylase, CYP7A, is expressed exclusively in the liver. molecular basis for cholesterol catabolism is largely unknown. Overexpression of CYP7A in hamsters results in a reduction of The major catabolic pathway for cholesterol removal is the serum cholesterol levels, suggesting that the enzyme plays a production of bile acids, which occurs exclusively in the liver central role in cholesterol homeostasis. Here, we report the (10). Cholesterol 7a-hydroxylase (Cyp7a), a member of the identification of a hepatic-specific transcription factor that cytochrome P450 family, is the first and rate-limiting enzyme binds to the promoter of the human CYP7A gene. We designate in a major bile acid biosynthetic pathway (11). The expression this factor CPF, for CYP7A promoter binding factor. Mutation of CYP7A is tightly regulated. The CYP7A gene is expressed of the CPF binding site within the CYP7A promoter abolished exclusively in the liver where it is induced by dietary cholesterol hepatic-specific expression of the gene in transient transfec- and suppressed by bile acids (11–13). Several independent lines tion assays. A cDNA encoding CPF was cloned and identified of evidence indicate that cholesterol catabolism plays a central as a human homolog of the Drosophila orphan nuclear recep- role in cholesterol homeostasis. Treatment of laboratory an- tor fushi tarazu F1 (Ftz-F1). Cotransfection of a CPF expres- imals with colestipol or cholestyramine, two bile acid binding sion plasmid and a CYP7A reporter gene resulted in specific induction of CYP7A-directed transcription. These observa- resins, decreases serum cholesterol levels (11, 12, 14, 15). In tions suggest that CPF is a key regulator of human CYP7A gene addition, overexpression of the CYP7A gene in hamsters expression in the liver. reduces total cholesterol and low density lipoprotein choles- terol levels (16). Thus, regulating the production of Cyp7a represents a potential therapeutic strategy for the discovery of In mammalian cells, cholesterol is an essential membrane new cholesterol-lowering drugs. component and is required for the synthesis of both sterols and HepG2 cells, a hepatoma-derived cell line, were used as a nonsterols necessary for normal cell function. Excess choles- terol causes the formation of toxic precipitates in cells, which model system to investigate the molecular mechanisms under- may accumulate on arterial walls and eventually lead to lying hepatic-specific expression of the human CYP7A gene atherosclerosis (1). It is therefore crucial that cholesterol levels (17). In this report, we used DNase I hypersensitivity mapping are maintained under tight control at all times. Three major to characterize the human CYP7A promoter. These studies led regulatory pathways are involved in the maintenance of cel- to the discovery of a hepatic-specific regulatory element within lular cholesterol homeostasis: (i) uptake of dietary cholesterol the CYP7A promoter. We then cloned the gene encoding a via the low density lipoprotein (LDL) receptor, (ii) endoge- CYP7A promoter binding protein and identified it as a human nous cholesterol biosynthesis, and (iii) metabolic conversion of homolog of the orphan nuclear receptor fushi tarazu F1 cholesterol to bile acids (2). The link among these regulatory (Ftz-F1) from Drosophila (18). This transcription factor, des- pathways is cholesterol itself. Cholesterol serves as a feedback ignated CYP7A promoter binding factor (CPF), represents a or feed-forward signal, coordinating the expression of key specific transcriptional inducer of human CYP7A gene expres- genes whose products are involved in these pathways (3). When sion. intracellular cholesterol levels are elevated, the transcription of genes encoding the LDL receptor and cholesterol biosyn- MATERIALS AND METHODS thetic enzymes [including hydroxymethyl glutaryl (HMG)- CoA synthase and HMG-CoA reductase] is suppressed. This Cells and Plasmids. HepG2 (a human hepatoma cell line), negative feedback process is mediated by a family of transcrip- HEK293 (a transformed human embryonic kidney cell line), tion factors designated sterol regulatory element binding and Caco2 (a human colon adenocarcinoma cell line) were proteins (SREBPs) (4–6). SREBPs contain an N-terminal purchased from American Type Culture Collection. SV589, a transcription factor domain, a DNA-binding basic helix–loop– transformed human fibroblast cell line, was a gift from Michael helix–leucine zipper motif, two hydrophobic transmembrane Brown and Joseph Goldstein (University of Texas Southwest- domains that anchor the protein in the endoplasmic reticulum ern Medical Center, Dallas). Cells were cultured in DMEMy (ER), and a C-terminal regulatory domain (6). When intra- Ham’s F-12 (1:1) supplemented with 10% FCS at 37°C, 5% cellular cholesterol levels are low, a two-step proteolytic CO2 in a humidified incubator. cascade releases the N-terminal transcription factor domain of SREBP from the ER membrane (7–9). The transcription Abbreviations: CYP7A, cholesterol 7a-hydroxylase; CPF, CYP7A factor then enters the nucleus and activates sterol response promoter binding factor; EMSA, electrophoretic mobility-shift assay; element-regulated genes (7–9). mLRH-1, mouse liver receptor homolog. Data deposition: The sequence reported in this paper has been The publication costs of this article were defrayed in part by page charge deposited in the GenBank database (accession no. AF146343). *Present address: Sumitomo Pharmaceuticals Research Center, 1–98, payment. This article must therefore be hereby marked ‘‘advertisement’’ in Kasugadenaka 3-chome, Konohana-ku, Osaka, Japan. accordance with 18 U.S.C. §1734 solely to indicate this fact. †To whom reprint requests should be addressed. e-mail: shan@ PNAS is available online at www.pnas.org. tularik.com. 6660 Downloaded by guest on September 24, 2021 Biochemistry: Nitta et al. Proc. Natl. Acad. Sci. USA 96 (1999) 6661 pGL3CYP7Awt was constructed by subcloning the 2716y (1 3 107) were cultured in media containing 100 mCiyml of 114 fragment of the human CYP7A gene (a gift from David [35S]methionine for 90 min. Cells were harvested and then Russell, University of Texas Southwestern Medical Center) lysed by three freeze-thaw cycles in buffer containing 50 mM into the pGL3-luciferase reporter plasmid (Promega). TriszHCl (pH 7.5), 125 mM NaCl, 5 mM EDTA, and 0.1% pGL3CYP7Am-129y130 and pGL3CYP7Am-61y62 contain (volyvol) NP-40. Cell lysates then were used for immunopre- mutations at positions 2129 and 2130 (GG to TT) and 261 cipitation with the anti-CPF antibody. Precipitated samples and 262 (AA to TC), respectively. The two base-pair substi- were resolved by 10% SDSyPAGE, and the gels were dried and tutions were introduced into pGL3CYP7Awt by using the exposed to x-ray film. ExSite mutagenesis kit (Stratagene). pfCPF contains a Flag 9 epitope-tagged sequence at the 5 end of the CPF gene cloned RESULTS into pcDNA3 (Invitrogen). Nuclear receptors used in this study were cloned by PCR using QUICK-Clone cDNA pur- DNase I-Hypersensitive Site Mapping of the Human CYP7A chased from CLONTECH. Gene. The DNase I-hypersensitive mapping technique was DNase I Hypersensitivity Mapping. HepG2, HEK293, or used to identify potential hepatic-specific regulatory regions of Caco2 cells (3 3 106) were harvested and lysed in a buffer (1.5 the human CYP7A gene. DNase I hypersensitivity is known to ml) containing 50 mM TriszHCl (pH 7.9), 100 mM KCl, 5 mM be associated with the open chromatin conformations of y MgCl2, 0.05% (vol vol) saponin, 200 mM 2-mercaptoethanol, regulatory regions near transcriptionally active genes (22). and 50% (volyvol) glycerol. Nuclei were collected by centrif- Nuclei prepared from HepG2, HEK293, and Caco2 cells were ugation and resuspended in a buffer containing 100 mM NaCl, treated with increasing amounts of DNase I. The DNAs then z 3 50 mM Tris HCl (pH 7.9), 3 mM MgCl2,1mMDTT,1 were extracted, digested with PstI, transferred onto nylon, and complete protease inhibitor mixture (Boeringer Mannheim), hybridized with a radio-labeled fragment containing nucleo- and sequentially diluted DNase I (0.6, 1.7, or 5 unitsyml). tides 2944 to 2468 of the CYP7A gene. As indicated in Fig. 1A, Nuclei suspensions were incubated at 37°C for 20 min. The this probe hybridized to the predicted 5-kb PstI fragment in reactions were terminated by addition of EDTA to a final DNA isolated from all cell types examined. However, a second concentration of 100 mM. After RNase A and Proteinase K 2.8-kb DNA fragment was detected with the same probe and treatment, genomic DNA was prepared and subjected to found only in HepG2 cells. As DNase I treatment was ex- Southern hybridization (19). tended, the intensity of the 2.8-kb DNA band increased, while Electrophoretic Mobility-Shift Assay (EMSA). Nuclear ex- the intensity of the parental 5-kb DNA band diminished tracts were prepared from cultured cells by the method of concomitantly. These observations revealed the existence of a Schreiber et al. (20), except that KCl was used instead of NaCl DNase I-hypersensitive site located roughly 200 bp upstream at the indicated concentration. In vitro transcription and from the CYP7A transcription start site. The 2.8-kb band was translation reactions were performed with the TNT system observed only in HepG2 cells and not in HEK293 or Caco2 (Promega).
Recommended publications
  • Enabling Comprehensive Assessments of Drug–Drug Interaction Risks
    R&D Solutions for PHARMA & LIFE SCIENCES PHARMACOVIGILANCE Enabling Comprehensive Assessments of Drug–Drug Interaction Risks Summary Dr. Kevin Lustig, President and CEO of The Assay Depot, Inc., and Dr. Maria Thompson, Principal Consultant, look at the dynamics of drug metabolizing enzymes and transporters and how an understanding of this critical aspect of biology enables assessments of drug–drug interaction risks. In addition, they comment on PharmaPendium®, which includes the DMPK solution with its DDI Risk Calculator, as an important tool in making these assessments successfully. Thanks to its comprehensive data on METs, PharmaPendium offers a unique platform for modeling advanced drug interactions. Abstract Understanding the dynamics of drug metabolizing enzymes and transporters (METs) is critical to successful drug development. MET behavior can significantly impact drug safety. Many factors regulate enzymes and transporters, which in turn affect the pharmacokinetic properties of drugs and mediate drug interactions. Evaluation of drug interaction profiles required detailed in vitro and in vivo studies along with predictive modeling. Thanks to its comprehensive data on METs, PharmaPendium offers a unique platform for modeling advanced drug interactions. This MET data and the ability to predict drug–drug interactions (DDIs) are incredibly valuable for optimized research workflows and accelerated drug development. They enable intelligent, in silico drug design and provide scientists with comprehensive knowledge about drug metabolism, significantly reducing the need for costly and time-consuming lab work and animal models and informing critical decisions on clinical trial design. Introduction Every successful drug discovery and development effort needs to factor in drug efficacy and safety, both of which are intimately linked to drug metabolism.
    [Show full text]
  • July Updates: People and Places
    career news July Updates: People and Places Skills and knowledge transfer alpha-synuclein A53T knock-in model; and commented in a press release, The NC3Rs has awarded a total of £219,339 the continued development of a pre-clinical “The partnership enables Scientist.com this year to three researchers through the model to test LRRk2 kinase inhibitors as a users to easily access innovative rodent 2018 NC3Rs Skills and Knowledge Transfer treatment for PD. models generated with the latest funding competition, designed to promote CRISPR technology.” the post-development uptake of new 3Rs Easi editing approaches. Laura Scullion Hall from The University of Nebraska recently Understanding aging fat the University of Stirling will partner with licensed its Easi-CRISPR gene editing Kristy Townsend, a neurobiologist at the pharmaceutical company GSK to develop technology to Taconic Biosciences. The University of Maine in Orono, has received an online learning platform for research dog CRISPR variant, developed by Masato a three-year $750,000 grant from the handling and welfare. Jonathan Brown from Ohtsuka at the University of Tokyo and American Heart Association to study links the University of Exeter will use the award Channabasavaiah Gurumurthy at the between fat tissue and cardiovascular and to apply the TaiNI wireless EEG recording University of Nebraska, enables the site- metabolic diseases in aging mouse models. technology he developed with scientists at specific insertion of large sequences Recent work from her lab has revealed Eli Lilly through the NC3Rs CRACK IT of DNA, an improvement to previous evidence of “adipose neuropathy”—fat Challenge to dementia research in mice.
    [Show full text]
  • Drug Discovery Chemistry
    Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT
    [Show full text]
  • Understanding Key Determinants of Drug Activity
    CASE STUDY Dr. Kevin Lustig, President and CEO, The Assay Depot, Inc. Greater San Diego Area Understanding Key Determinants of Drug Activity SUMMARY This article highlights the increasing role that drug metabolism and transport proteins have in the drug approval process. CASE STUDY: The Assay Depot, Inc. The dynamics of drug metabolizing enzymes and transporters is critical to the development of personalized medicine strategies. Abstract / Summary The dynamics of drug metabolizing enzymes and transporters is critical to the develop- ment of personalized medicine strategies. A multitude of factors regulate enzymes and transporters, which in turn affect the pharmacokinetic properties of drugs and medi- ate drug interactions. Evaluation of drug interaction profiles is a critical step in drug development and necessitates detailed in vitro and in vivo studies along with predictive modeling. PharmaPendium® via its Metabolizing Enzymes and Transporters Module provides unprecedented depth of data on drug metabolizing enzymes and transporters and offers a unique platform for modeling advanced drug interactions. This Module will prove to be a valuable resource capable of improving workflows and accelerating devel- opment by enabling intelligent, in silico drug design. By providing scientists with all of the available knowledge about drug metabolism, we can significantly reduce the need for costly and time-consuming lab work and animal models. Requiring these only to answer the true unknowns where no one else has gone before. Introduction Every successful drug discovery and development effort needs to factor in drug efficacy Dr. Kevin Lustig, Author and safety, both of which are intimately linked to drug metabolism. Hence knowledge President & CEO, The Assay Depot Inc.
    [Show full text]
  • Strategic Outsourcing of Pharmaceutical R&D
    CHEMSITRY TODAY Vol 31(4) P. 14-17 / CROS/CMOS Strategic outsourcing of pharmaceutical R&D - Bringing pharma and drug discovery into the information age KEVIN LUSTIG Assay Depot, Inc Corresponding Author KEVIN LUSTIG: Assay Depot, Inc, email: [email protected] KEYWORDS: Outsourcing; innovation; lean; drug; research; discovery ABSTRACT: The centralized model of pharmaceutical development that was used successfully through most of the last century is no longer a good fit. Advances in modern molecular research have changed the playing field to such an extent that the old model is no longer viable. If drug companies can solve the problems of pre-clinical development and deliver a steady stream of new, high- quality compounds to the clinic, then the challenges currently facing pharma will become a thing of the past. The single most likely route to success is through the application of strategic outsourcing, which if done correctly, can dramatically reduce research costs while simultaneously improving research quality. Utilizing new online tools such as research exchanges, a “lean” pharmaceutical company can find and manage a large number of specialist scientific service providers and experts that can bring exactly the right skill set to bear at the right time in the project cycle. INTRODUCTION Few would argue that the Pharmaceutical Industry has been languishing in the doldrums now for well over a decade. Pharmaceutical companies are having to face three major issues involving drug approvals, development costs and patents expirations. Any of these alone would prove a tough nut to crack, but the fact that they are all converging at the same time is creating a perfect storm! • A paucity of new drug approvals: 2010 was one of the worst years on record, with the European Medicines Agency showing only 41 finalized applications, compared to 125 in 2009.
    [Show full text]
  • Marketplaces for Sharing Scientific Data and Outsourcing R&D Activities: the Case Study of the Pharmaceutical, Life Sciences and Bio-Medical Industries
    MARKETPLACES FOR SHARING SCIENTIFIC DATA AND OUTSOURCING R&D ACTIVITIES: THE CASE STUDY OF THE PHARMACEUTICAL, LIFE SCIENCES AND BIO-MEDICAL INDUSTRIES In the present document, we aim to review the main protagonist companies in the field of the outsourcing of biomedical R&D research and in the sharing of scientific data and contract- research consultancy services. This effort is part of a longer-term objective aimed at assessing the current state of the R&D outsourcing market via “marketplace” type of websites, in order to estimate the existing potential competition to the core areas of interest of the VIMMP project. Even though, under the current state of affairs, no direct competitors of VIMMP presently exist (within the restricted field of materials modelling coupled with marketplace and data/software sharing type of functionalities), marketplace websites active in other branches of science and technology can still provide invaluable insight in demonstrating how such R&D commercial operations can be implemented and exploited successfully and profitably. 1. General Introduction to R&D Outsourcing Services Advances in science, technology, and engineering impact our daily lives and fuel economic growth and prosperity. Investment in innovation and R&D drives these advances, and it is the hi-tech companies and their respective industries that dominate global R&D spending. Hardware/software, electronics, automotive, aerospace and defense, telecommunications, and pharmaceutical/biotech all feature as the highest R&D spending industries. The pharmaceutical/biotech industry has the highest levels of R&D outsourcing across hi-tech industries, with its outsourcing growth rate outstripping internal investments. Some large pharmaceutical companies suggest that 40% or more of their R&D spend will be outsourced in the near future, and that clinical operations functions will eventually be outsourced entirely.
    [Show full text]
  • Motility of Acta Protein-Coated Microspheres Driven by Actin Polymerization
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 4908–4913, April 1999 Biophysics Motility of ActA protein-coated microspheres driven by actin polymerization LISA A. CAMERON*, MATTHEW J. FOOTER†,ALEXANDER VAN OUDENAARDEN‡, AND JULIE A. THERIOT†§¶ *Department of Biological Sciences, Stanford University, Stanford, CA 94305-5020; †Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305-5307; ‡Department of Chemistry, Stanford University, Stanford, CA 94305-5080; and §Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305-5124 Communicated by James A. Spudich, Stanford University School of Medicine, Stanford, CA, March 1, 1999 (received for review January 12, 1999) ABSTRACT Actin polymerization is required for the gen- moving endosomes (J. Heuser, personal communication) and eration of motile force at the leading edge of both lamellipodia phospholipid vesicles (11). Although much is understood and filopodia and also at the surface of motile intracellular about the biochemical mechanisms of catalyzing actin filament bacterial pathogens such as Listeria monocytogenes. Local polymerization in several of these systems (12–14), relatively catalysis of actin filament polymerization is accomplished in little is known about how this local surface catalysis results in L. monocytogenes by the bacterial protein ActA. Polystyrene comet tail formation, force generation, and motility. It is beads coated with purified ActA protein can undergo direc- striking that a variety of biochemical mechanisms for cata- tional movement in an actin-rich cytoplasmic extract. Thus, lyzing local actin polymerization on the surface of a small the actin polymerization-based motility generated by ActA can object (bacterium, virus, or membrane vesicle) all result in the be used to move nonbiological cargo, as has been demon- same type of actin self-organization and movement.
    [Show full text]
  • Collaborative Drug Discovery's 10 Anniversary Community Meeting
    Collaborative Drug Discovery’s 10th Anniversary Community Meeting April 4th, 2014 8am-6pm UCSF Mission Bay Conference Center 1675 Owens St. San Francisco, CA 94158 Please use this Twitter hashtag for the event: #CDDx14 Agenda 7:45 Registration - refreshments in Foyer and Exhibition room 8:15 Opening Remarks - with UCSF Host, Stephanie Robertson and CDD CEO, Barry Bunin Collaborative Workflow: Basic and Advanced Use Cases of CDD Vault 8:20 Charlie Weatherall (CDD) & Anna Spektor (CDD) 9:10 Morning Sessions - moderated by Sylvia Ernst (CDD) The Rockefeller University Compound Screening Library 9:15 J. Fraser Glickman (Rockefeller University) Recent Progress in De-Orphanization of Nuclear Receptors 9:40 Ruo Steensma (Orphagen Pharmaceuticals) 10:05 Morning Break - located in the Foyer and Exhibition room Large small molecules in a Small large molecule world 10:35 Leanna Staben (Genentech) Linking the Molecular Structure of Medicines to their Biological Effects 11:00 Bob Volkmann (Systamedic & Mnemosyne Pharmaceuticals) Panel: Externalized Research - What Makes a Good Partnership? Wisdom from Experts 11:25 Who've "Been There - Done That," moderated by Sylvia Ernst (CDD) 11:50 Lunch - boxed lunches in the Foyer and Exhibition room Optional: “What if CDD had...” provide feedback to our product team (12:35) Kellan Gregory (CDD) 10 Years Evolving Our Collaborative Drug Discovery Vaults 1:05 Barry Bunin (CDD) CDD Vault: Noteworthy recent enhancements and a preview of things to come 1:30 David Blondeau (CDD) & Kellan Gregory (CDD) 2:20 Afternoon sessions - moderated Christopher Lipinski The Tuberculosis Drug Accelerator: A New Paradigm For Drug Discovery 2:25 Jerry Shipps (Tuberculosis Drug Accelerator) The role of NIAID in the development of therapeutics for Infectious Diseases 2:50 Martin John Rogers (NIAID) 3:15 Afternoon Break - located in the Foyer and Exhibition Room Targeting the Immunoproteasome 3:40 Dustin L.
    [Show full text]
  • Helping the Life Science Industry Accelerate R&D
    12 www.sdbj.com AUGUST 16, 2021 SPECIAL REPORT: LIFE SCIENCES Helping the Life Science Industry Accelerate R&D San Diego’s Biotech Boom Backed By Research Institutions and Contract Organizations By NATALLIE ROCHA Local life science companies big and small have been going public and securing funding to advance their re- search and drug pipelines in what could be described as a biotech boom. For many of these commercial companies, they turn to contract research organizations (CROs) and contract manufacturing organizations (CMOs) to help them get the job done. Additionally, the area’s life science research institutes have played a crucial role in meeting this mo- ment of industry growth and delivering innovative work that translates to healthcare solutions. The San Diego Business Journal connected with a few of the organizations that are supporting the life science industry and driving innovation. Helping Companies Scale In Q2 of this year, venture capital funding totaled $2 billion and almost half of these deals were with fast-grow- ing life science companies. In recent months, startups have received funding, M&A deals have popped up and more than 10 biotech companies have gone public through IPOs and SPAC mergers. Larger pharmaceutical companies often have the re- sources and manpower to conduct R&D operations in- house if they choose. With capital in hand, these smaller companies are moving fast and the need to scale leads many biotech companies to rely on contracting organi- zations to help them make it happen. For instance, Metacrine, a clinical-stage biopharma- Photo Courtesy of Ajinomoto Bio-Pharma Services ceutical company that specializes in therapies for patients Ajinomoto Bio-Pharma Services recently announced that it will open a high-speed multi-purpose fill-finish line in its state-of- with liver and gastrointestinal (GI) diseases, announced the-art commercial manufacturing facility in San Diego.
    [Show full text]
  • Wake Forest Journal of Business and Intellectual Property Law
    WAKE FOREST JOURNAL OF BUSINESS AND INTELLECTUAL PROPERTY LAW VOLUME 20 WINTER/SPRING 2020 NUMBER 2 FASTER SCIENCE: WHY SCIENTIST.COM’S BLOCKCHAIN APPROACH IS THE ANSWER TO THE PHARMACEUTICAL INDUSTRY’S 21 C.F.R. PART 11 COMPLIANCE CHALLENGES Kelly Kagan† ABSTRACT ............................................................................ 3 INTRODUCTION .................................................................... 3 I. BACKGROUND ................................................................... 9 A. BACKGROUND ON DRUG REGULATION ...................... 10 B. BACKGROUND ON PART 11 ......................................... 13 1. 1997 Introduction of Part 11 ..................................... 13 2. 2003 AMENDMENT TO PART 11 ..................................... 15 C. PART 11’S CURRENT CHALLENGES ............................ 17 1. New Drug Development and Outsourcing in a GloBal Market ............................................................. 17 2. FDA Warnings and Loss of Goodwill ....................... 27 3. Implications of an FDA Disapproval of an NDA ...... 29 4. Contracting and Material Breach ............................. 33 II. PREVIOUS SOLUTIONS HAVE FAILED .......................... 36 III. BLOCKCHAIN FACILITATES PART 11 COMPLIANCE .................................................................... 37 A. THE STRENGTHS OF BLOCKCHAIN .............................. 38 1. Blockchain Ensures Data Integrity By Ensuring Access and Change Controls ...................................... 38 2. Blockchain Reduces the Costs
    [Show full text]
  • Planning for Future Research in Public Universities in Uncertain Times
    Planning for Future Research in Public Universities in Uncertain Times Merrill Series on The Research Mission of Public Universities A compilation of papers originally presented at a retreat sponsored by The Merrill Advanced Studies Center July 2014 Mabel L. Rice, Editor Technical editor: Evelyn Haaheim MASC Report No. 118 The University of Kansas © 2014 The University of Kansas Merrill Advanced Studies Center or individual author TABLE OF CONTENTS MASC Report No. 118 Introduction Mabel L. Rice ..................................................................................................................... vi Director, Merrill Advanced Studies Center, the University of Kansas Executive summary ......................................................................................................... viii Keynote address Sally Frost Mason ........................................................................................................... 1 President, the University of Iowa Planning for Future Research in Public Universities in Uncertain Times Panel 1: Research Administrators Harvey Perlman ............................................................................................................. 19 Chancellor, University of Nebraska Engaging with the Private Sector: Nebraska Innovation Campus Brian Foster ...................................................................................................................... 25 Provost and Professor Emeritus, University of Missouri Adaptive Planning in a Chaotic Research Environment:
    [Show full text]
  • San Diego Business Journal Supplement
    SAN DIEGO BUSINESS JOURNAL SUPPLEMENT TITLE SPONSOR GOLD SPONSORS IN PARTNERSHIP WITH Page A16 www.sdbj.com MOST ADMIRED CEO SUPPLEMENT December 16, 2013 Access to Expertise Steadfast Relationships Comprehensive Solutions Financial Integrity Chase Congratulates the 2013 Most Admired CEOs. Chase Commercial Banking is committed to helping mid-sized businesses across San Diego achieve their goals. Chase offers you the local delivery of global capabilities and award-winning industry expertise. Just like you, your dedicated Chase banker is a part of San Diego and understands the unique needs of the businesses that operate here. Through our partnership, we will deliver tailored fi nancial solutions and fi rst-class client service that will position you for success. Chase takes pride in strengthening the communities we serve by helping local businesses thrive. Let us do the same for you. Contact Brennon Crist, San Diego Market Manager, Middle Market Banking at (619) 358-6361 or visit chase.com/commercialbanking for more information. COMMERCIAL BANKING © 2013 JPMorgan Chase & Co. All rights reserved. Chase, JPMorgan and JPMorgan Chase are marketing names for certain businesses of JPMorgan Chase & Co. and its subsidiaries worldwide (collectively, “JPMC”). Products and services may be provided by commercial bank affi liates, securities affi liates or other JPMC affi liates or entities. PA_13_464 December 16 , 2013 MOST ADMIRED CEO SUPPLEMENT www.sdbj.com Page A17 Letter From The San Diego Business Journal elcome to the San Diego Business Journal’s seventh annual Most Admired CEO publication. In the following pages we are pleased to present a repertoire of San Diego’s most dynamic and innovative business leaders.
    [Show full text]